MétaCan
Menu
Back to cohort
Record W2617478395 · doi:10.1016/j.trci.2017.04.007

Power analysis to detect treatment effects in longitudinal clinical trials for Alzheimer's disease

2017· article· en· W2617478395 on OpenAlexfundno aff
Zhiyue Huang, Graciela Muñiz‐Terrera, Brian D. M. Tom

Bibliographic record

VenueAlzheimer s & Dementia Translational Research & Clinical Interventions · 2017
Typearticle
Languageen
FieldMedicine
TopicDementia and Cognitive Impairment Research
Canadian institutionsnot available
FundersNational Institute of Biomedical Imaging and BioengineeringNational Institutes of HealthGenentechIXICOH. Lundbeck A/SServierCanadian Institutes of Health ResearchInnovative Medicines InitiativeEisaiEuropean Federation of Pharmaceutical Industries and AssociationsPfizerNovartis Pharmaceuticals CorporationF. Hoffmann-La RocheMedical Research CouncilBiogenEli Lilly and CompanyBristol-Myers SquibbBioClinicaU.S. Department of DefenseAlzheimer's Disease Neuroimaging InitiativeMeso Scale DiagnosticsNational Institute on AgingAlzheimer's Association
KeywordsClinical Dementia RatingClinical trialDementiaRating scaleDiseaseAlzheimer's diseaseCognitionMini–Mental State ExaminationSample size determinationPopulationMultivariate statisticsProdromal StagePsychologyClinical psychologyMedicinePsychiatryInternal medicineStatisticsDevelopmental psychology

Abstract

fetched live from OpenAlex

INTRODUCTION: Assessing cognitive and functional changes at the early stage of Alzheimer's disease (AD) and detecting treatment effects in clinical trials for early AD are challenging. METHODS: Under the assumption that transformed versions of the Mini-Mental State Examination, the Clinical Dementia Rating Scale-Sum of Boxes, and the Alzheimer's Disease Assessment Scale-Cognitive Subscale tests'/components' scores are from a multivariate linear mixed-effects model, we calculated the sample sizes required to detect treatment effects on the annual rates of change in these three components in clinical trials for participants with mild cognitive impairment. RESULTS: Our results suggest that a large number of participants would be required to detect a clinically meaningful treatment effect in a population with preclinical or prodromal Alzheimer's disease. We found that the transformed Mini-Mental State Examination is more sensitive for detecting treatment effects in early AD than the transformed Clinical Dementia Rating Scale-Sum of Boxes and Alzheimer's Disease Assessment Scale-Cognitive Subscale. The use of optimal weights to construct powerful test statistics or sensitive composite scores/endpoints can reduce the required sample sizes needed for clinical trials. CONCLUSION: Consideration of the multivariate/joint distribution of components' scores rather than the distribution of a single composite score when designing clinical trials can lead to an increase in power and reduced sample sizes for detecting treatment effects in clinical trials for early AD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.481
metaresearch head score (Gemma)0.696
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Simulation or modeling · Consensus signal: none
GenreCandidate signal: Methods · Consensus signal: Methods
Teacher disagreement score0.481
Threshold uncertainty score0.640

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.4810.696
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0080.008
Bibliometrics0.0050.004
Science and technology studies0.0010.004
Scholarly communication0.0030.005
Open science0.0030.004
Research integrity0.0060.005
Insufficient payload (model declined to judge)0.0070.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.595
GPT teacher head0.635
Teacher spread0.040 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designSimulation or modeling
Domainnot available
GenreMethods

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations9
Published2017
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia Translational Research & Clinical InterventionsSame topicDementia and Cognitive Impairment ResearchFrench-language works237,207